CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 64 enrolled
Drug / intervention
Ticagrelor +3 moredrug
Likely dose
Ticagrelor 90mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02383771
NCT02383771Phase 4Completed
CompareCT.gov

Reversal of the Anti-platelet Effects of Ticagrelor in Healthy Persons and Patients With Coronary Artery Disease

The First Affiliated Hospital with Nanjing Medical University·interventional·Posted Mar 9, 2015·Updated Aug 16, 2017

In Brief

A Phase 4 clinical trial evaluating Ticagrelor, Aspirin + Ticagrelor, and 1 other intervention for Coronary Artery Disease. Completed, enrolled 64 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the proportion of untreated donor platelets required to fully reverse the platelet inhibitory effects of ticagrelor and aspirin in healthy persons and patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) and receiving ticagrelor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesChina
CollaboratorsNational Natural Science Foundation of China

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 9, 2015
Enrollment StartMar 1, 2015
Primary CompletionNov 1, 2016
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.3 years ago

Interventions

Ticagrelordrug

(Ticagrelor 90mg Bid) x 7days

Aspirin + Ticagrelordrug

(Aspirin 100mg daily + Ticagrelor 90mg Bid) x 7days

Controldrug

No Anti-platelet Therapy

Aspirin + Ticagrelordrug

Dual anti-platelet therapy (Aspirin 100mg daily + Ticagrelor 90mg Bid) after percutaneous coronary intervention (PCI)